AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00662974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal massage with almond oil during the second stage of labor
Description: 30 ml of oil applied during labor
Study NCT02144740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
Study NCT02144740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
Study NCT00980551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subtenon Carboplatin
Description: Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
Study NCT00980551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
Study NCT00980551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
Study NCT00980551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
Study NCT04277091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Arm-cranking exercise
Study NCT04277091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuos training
Description: Arm-cranking exercise
Study NCT03007394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin Capsule
Study NCT03007394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: sugar pill to mimic lorcaserin 10mg capsule
Study NCT02552316 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NB-UVB Phototherapy
Study NCT03132051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid injection
Description: ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
Study NCT03577665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: curative proton therapy
Description: Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Study NCT00151775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily
Study NCT00151775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Cohorts A, B, C: placebo, once daily
Study NCT00151775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg
Study NCT02539329 — intervention group
Intervention type: OTHER
Intervention: Neurological assessment and Blood sample
Description: Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
Study NCT04121468 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Each tablet contains 500mg of metformin hydrochloride
Study NCT04121468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Each tablet contains no active drug ingredient
Study NCT03788239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staples versus sutures
Description: Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples.
Study NCT00470301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00470301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00470301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study NCT00470301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02177461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Study NCT02177461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Study NCT02177461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT01400607 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)
Description: The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
Study NCT01400607 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microfracture
Description: Marrow stimulation using the microfracture technique; performed arthroscopically
Study NCT02947646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ ON
Description: experimental intervention
Study NCT02947646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ OFF
Description: active comparator
Study NCT00952029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00952029 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00952029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT02174991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor (AR-12286)
Study NCT01373658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yinyi stent
Description: subjects with Yinyi stent implantation
Study NCT03106064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting independence in self-care
Description: The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
Study NCT03106064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual hospital care
Study NCT04569292 — intervention group
Intervention type: OTHER
Intervention: No intervention on patients
Description: No intervention on patients
Study NCT01862523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
Study NCT01862523 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: diluent
Description: diluent
Study NCT00123318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 50mg/m2 IV day 1
Study NCT00123318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 IV day 1
Study NCT00123318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
Study NCT00123318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy 25 Fractions, 5 days/week for 5 weeks
Study NCT04270708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
Study NCT04270708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclofos 100 MG/ML
Description: Patients with Autism will be treated with oral Triclofos as a sedative for EEG
Study NCT04233203 — intervention group
Intervention type: DRUG
Intervention: Insulin Faster Aspart
Description: Currently receiving Faster Aspart during 3 or more months.
Study NCT04233203 — intervention group
Intervention type: DEVICE
Intervention: Insulin pump
Description: Currently receiving CSII therapy during 6 or more months.
Study NCT00075621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: filgrastim
Description: 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
Study NCT00075621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: melphalan
Description: 200 mg/kg over 2 days
Study NCT00075621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous peripheral blood stem cell transplantation
Description: autologous peripheral blood stem cell transplantation
Study NCT03625284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Edible oil
Study NCT03625284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FucoVital
Description: Microalgae oil extract
Study NCT03625284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: FucoVital
Description: Microalgae oil extract
Study NCT03334032 — intervention group
Intervention type: OTHER
Intervention: Inpatient treatment for Anorexia nervosa
Description: Nutritional rehabilitation in a clinic with specialized eating disorder service
Study NCT02610582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rAAV.hCNGA3
Description: Single subretinal injection of rAAV.hCNGA3
Study NCT02849119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic or robotic partial nephrectomy
Description: Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
Study NCT02197702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
Study NCT02197702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
Study NCT00855816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: relaxation training
Study NCT02177188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBNP Lower Bodi Negative Pressure Chamber
Study NCT01858363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
Study NCT01858363 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare Percutaneous Transluminal Angioplasty Balloon Catheter
Study NCT04004910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma soluble TNF receptor pulldown
Description: The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.
Study NCT03962803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Description: three-dose, 20 µg per dose
Study NCT03962803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 20 µg per dose
Study NCT03962803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
Description: four-dose, 60 µg per dose
Study NCT00075335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100 (Mozobil plerixafor)
Description: AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
Study NCT05286190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Bupivacaine 0.25% Injectable Solution
Study NCT03618264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miscible liquid of dexamethasone and ropivacaine
Description: Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT04004910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma soluble TNF receptor pulldown + chemotherapy
Description: The Immunoadsorption affinity column, the LW-02 column, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the Immunopheresis® procedure is combined with low dose chemotherapy to potentially enhancing the latter's cytotoxic effect.
Study NCT03618264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study NCT04004910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy Drugs, Cancer
Description: Low dose chemotherapy will be provided to patient either IV or oraly depending on the regimen used.
Study NCT04526912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Single subcutaneous dose
Study NCT04526912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous single dose matched to VIB7734.
Study NCT02837458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency
Description: high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT02837458 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
Study NCT03174366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
Study NCT01255891 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Androgen suppression plus radiation therapy
Description: Adjuvant androgen suppression plus radiation therapy
Study NCT02636205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo therapy
Description: Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
Study NCT04142801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeMo web application
Description: The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
Study NCT04142801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: the patient have the classical follow up at the memory center (consultation)
Study NCT02016651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right side position
Description: Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
Study NCT03992352 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Age 60+ with planned HCT for Hematologic Malignancy
Description: questionnaires, geriatric assessments
Study NCT04354662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg d1
Study NCT04354662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1;
Study NCT04354662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m², d1
Study NCT04354662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1
Study NCT04354662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1
Study NCT01004926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echelon foot
Description: One Echelon foot for each subject, for a period of a month.
Study NCT01753635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway placement and use
Study NCT01753635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway placement and use
Study NCT01458535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets
Study NCT01458535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: tablets
Study NCT04098341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection
Description: All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
Study NCT02508623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550 mg tablet BID for 60 days
Study NCT02508623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID for 60 days
Study NCT02883972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention letter
Description: Behavioural-insight informed letter template
Study NCT02883972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control letter
Description: Invitation letter used by local area last year (updated as required)
Study NCT02883972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control letter
Description: Invitation letter used by local area last year (updated as required)
Study NCT02883972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Behavioural-insight informed SMS/email reminder message to return consent form
Study NCT01894087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBI - Cohort 1
Study NCT01894087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TBI - Cohort 2